Abstract:B-Raf has been identified as promising targets for novel anticancer agents. To further explore the interactions between small molecules and B-Raf, and to elucidate structural characteristics that influence the B-Raf kinase activity, molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were performed on a dataset of 75 Type II inhibitors. Molecular docking was applied to explore the detailed binding process between the inhibitors and B-Raf kinase in its DFG-out inactive conformation. Based on the conformations obtained by molecular docking strategy, 3D-QSAR models, including comparative molecular field analysis (CoMFA) and comparative molecular similarity indexes analysis (CoMSIA), were constructed. The established 3D-QSAR models show significant statistical quality and satisfactory predictive ability, with high q(2) and r(2) values: CoMFA model (q(2) = 0.759, r(2) = 0.922), and CoMSIA model (q(2) = 0.685, r(2) = 0.945). The systemic external validation indicated that both CoMFA and CoMSIA models were quite robust and possess high predictive abilities with r(2) pred values of 0.633 and 0.708, respectively. Several key structural features accounting for the inhibitory activities of these compounds were discussed based on the 3D contour maps generated by the CoMFA and CoMSIA models, which were in good accordance with the docking results. These theoretical results rendered by 3D-QSAR models along with the docking may provide a useful reference for understanding the action mechanism and designing novel potential B-Raf inhibitors.

Design, Biological Evaluation and 3D QSAR Studies of Novel Dioxin-Containing Triaryl Pyrazoline Derivatives As Potential B-Raf Inhibitors.

Design, Modification and 3D QSAR Studies of Novel 2,3-Dihydrobenzo[b][1,4]dioxin-containing 4,5-Dihydro-1h-pyrazole Derivatives As Inhibitors of B-Raf Kinase.

Modification, Biological Evaluation and 3D QSAR Studies of Novel 2-(1,3-diaryl- 4,5-Dihydro-1h-pyrazol-5-yl)phenol Derivatives As Inhibitors of B-Raf Kinase.

Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Design and Biological Evaluation of Novel Triaryl Pyrazoline Derivatives with Dioxane Moiety for Selective BRAFV600E Inhibition.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Synthesis, Biological Evaluation of Novel 4,5-Dihydro-2h-pyrazole 2-Hydroxyphenyl Derivatives As BRAF Inhibitors.

Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAFV600E inhibitors

Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.

Design, synthesis and biological evaluation of novel benzo-α-pyrone containing piperazine derivatives as potential BRAF(V600E) inhibitors.

Molecular Docking and 3D-Qsar Studies on A Series of Fused Heterocyclic Amides As B-Raf Inhibitors

Design, Synthesis And Antitumoractivities Of Bis-Arylureas And Bis-Arylamides Based On 1h-Benzo[D]Imidazole Moiety As Novel B-Raf(V600e)/Vegfr2 Dual Inhibitors

Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.

Design, Synthesis and Biological Evaluation of Β-Carboline Derivatives As Novel Inhibitors Targeting B-Raf Kinase

Design, Synthesis, and Biological Evaluation of Pyrazole Derivatives Containing Acetamide Bond As Potential BRAFV600E Inhibitors.

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2